


Elvitegravir-d₈

Cat. No.:	HY-14740S
Molecular Formula:	C ₂₃ H ₁₅ D ₈ ClFNO ₅
Molecular Weight:	455.93
Target:	HIV Integrase; HIV; Isotope-Labeled Compounds
Pathway:	Metabolic Enzyme/Protease; Anti-infection; Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Elvitegravir-d ₈ is deuterium labeled Elvitegravir. Elvitegravir (GS-9137; JTK-303; D06677) is an HIV integrase inhibitor for HIV-1IIB, HIV-2EHO and HIV-2ROD with IC ₅₀ of 0.7 nM, 2.8 nM and 1.4 nM, respectively.
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.
- [2]. Shimura K, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). *J Virol.* 2008 Jan;82(2):764-74.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA